Scinai Immunotherapeutics Ltd. (SCNI) Plunges 15.5% After Peer-Reviewed Study

On July 30, 2025, Scinai Immunotherapeutics Ltd. (SCNI) experienced a significant drop of 15.5% in pre-market trading, marking a notable decline in its stock price.

Scinai's recent stock performance has been marked by significant volatility, with the company's shares surging and declining sharply within a short period. On July 29, 2025, the stock trended up by 30.29% and 15.12% at different points during the day, driven by the publication of a peer-reviewed study validating the disease-modifying potential of its experimental drug PC111. This study, published in the Journal of Dermatological Treatment, confirmed PC111's ability to prevent blister formation in pemphigus and SJS/TEN, positioning it as a potential blockbuster in a $1 billion market.

The broader biotechnology sector remains volatile, with mixed earnings and regulatory pressures affecting many companies. Scinai's gains reflect clinical validation, differentiating it from sector peers facing earnings and R&D challenges. This divergence highlights Scinai's unique catalyst—peer-reviewed clinical data—positioning it as a high-conviction trade in an otherwise cautious biotech environment.